Menten AI, Inc.

Menten AI, Inc. specializes in generative AI solutions for peptide therapeutics, utilizing advanced machine learning and physics-based modeling to accelerate drug design and development. Founded in 2018 in San Francisco, US, Menten AI, Inc. focuses on advancing drug discovery through its AI platform for peptide therapeutics.

The founders, Hans Melo and Tamás Görbe, have experience in technology and biotech sectors. In June 2020, Menten AI raised USD 4 million in Seed funding from Khosla Ventures, Uncork Capital, and other investors, totaling USD 4 million raised to date. Menten AI's primary offering is a generative AI platform specifically designed for the development of peptide therapeutics. The platform utilizes machine learning techniques combined with first-principles physics-based molecular modeling to address the significant challenges associated with traditional drug design, such as small datasets and computational limitations.

By generating its own data, the platform enables the design and optimization of novel peptides that exhibit desirable drug-like properties, including nanomolar potency, high plasma stability, cell permeability, and oral bioavailability. Targeting currently undruggable and hard-to-drug targets, Menten AI’s solutions serve a diverse client base that includes pharmaceutical companies and biotech firms engaged in drug discovery. The platform is positioned within global markets, particularly in North America and Europe, where there is a robust demand for innovative therapeutic solutions. Menten AI’s revenue model is structured around partnerships with pharmaceutical and biotechnology companies, primarily operating on a B2B basis.

The company engages clients through collaborative agreements that enable the use of its AI-driven platform for drug discovery, with potential transactions encompassing milestone payments based on clinical success and licensing fees associated with the commercialization of peptide therapeutics. The platform's flagship service focuses on delivering drug-like hit molecules within an expedited timeframe of eight weeks, significantly faster than traditional methods. As a result, clients benefit from reduced development cycles, allowing for quicker entry into the market with novel therapeutics. Revenue is generated through these strategic partnerships, which are structured to align with the client’s specific drug development needs.

Menten AI plans to leverage its recent Seed funding of USD 4 million raised in June 2020 to enhance its AI platform and develop new products targeting peptide therapeutics. The company aims to expand its market presence in Europe and Asia by 2024, with initiatives to establish partnerships with local biotech firms. The funding will support R&D initiatives and facilitate market entry strategies for new therapeutic solutions.